{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","groups":[{"description":"This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).","id":"OG000","title":"Imiquimod"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"12 weeks post treatment","title":"Percentage of Participants With Clinical and Histologic Remission","type":"PRIMARY","unitOfMeasure":"% of participants"}